Leukemia

Long-term results of a pivotal trial of acalabrutinib verify that it is effective and safe as first-line therapy for patients with chronic lymphocytic leukemia.

According to findings from a large clinical trial, the combination of ibrutinib and ublituximab is effective in treating patients with chronic lymphocytic leukemia.

The ASCEND trial confirmed that acalabrutinib, a next-generation targeted treatment, is more effective than traditional chemoimmunotherapy in patients with relapsed chronic lymphocytic leukemia.

Recently reported data show that fixed-duration treatment with venetoclax and obinutuzumab for 12 months is effective and tolerable in some patients with chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who require systemic therapy have a new chemotherapy-free combination regimen to consider.

The chemotherapy-free combination of venetoclax plus obinutuzumab has shown efficacy and tolerability in older patients with chronic lymphocytic leukemia. Adding acalabrutinib, a new targeted agent, may enhance the clinical benefits of this regimen, according to results of a clinical trial.

Cancer specialists are now able to use a new scoring system to decide when to start treatment for patients who have been diagnosed with chronic lymphocytic leukemia.

Alliance A041702 is a large clinical trial that is exploring whether adding venetoclax to the combination of ibrutinib and obinutuzumab can improve outcomes in patients with chronic lymphocytic leukemia.